- Trial phase
- Phase 3
- Time to market
- Topline Phase 3 results expected in 2028, NDA submission thereafter, potential FDA approval likely no earlier than 2029 if the trial succeeds.
- Why 6/10
- The next hard, dated catalyst is the interim analysis of the CRPS-RISE Phase 3 trial, announced in October 2026 following FDA feedback on a group sequential design that could allow early stopping. The interim analysis timing has not been specified but is expected within the next 6-12 months. Topline Phase 3 results are expected in 2028, with an NDA submission planned thereafter.
Watch for the timing and outcome of the CRPS-RISE interim analysis, which could allow the trial to stop early for efficacy or futility. The merger with Ambros is still being finalized (S-4/A filed November 10, 2026), and current HOWL shareholders face massive dilution, owning roughly 7% of the combined entity. The $150 million PIPE is expected to fund the company through topline results in 2028 and into 2029, reducing near-term financing risk.
Price Chart
Executive Summary
Neridronate is an injectable bisphosphonate being developed by Ambros Therapeutics (merging into Werewolf Therapeutics/HOWL via reverse merger) for Complex Regional Pain Syndrome Type 1 (CRPS-1), a rare, debilitating pain condition with no FDA-approved treatments. The drug has FDA Breakthrough Therapy, Fast Track, and Orphan Drug designations. A pivotal Phase 3 trial (CRPS-RISE) began dosing in June 2026, and in October 2026 the company announced a planned interim analysis under a group sequential design. The combined company is expected to be funded through topline results in 2028 and into 2029. However, the reverse merger structure means massive dilution for current HOWL shareholders, and the drug still faces the binary risk of Phase 3 failure.
How It Works
Neridronate is a bisphosphonate, a class of drugs that slow bone breakdown by inhibiting osteoclast activity. In CRPS-1, a condition involving severe chronic pain often accompanied by bone loss and inflammation, neridronate is thought to reduce pain by normalizing bone metabolism and reducing inflammatory signaling in the affected limb.
Trial Status
The pivotal CRPS-RISE Phase 3 trial (group sequential design) began dosing its first patient in June 2026. In October 2026, Ambros announced a planned interim analysis following FDA feedback, using a group sequential design that could allow the trial to stop early. The trial is designed to support an FDA regulatory submission for neridronate in CRPS-1.
The Two-Sided Case
Upcoming Catalysts
- Interim analysis of the CRPS-RISE Phase 3 trial (timing not yet specified, announced October 2026)
- Completion of the merger with Ambros Therapeutics and Nasdaq ticker change (expected to close after shareholder vote; S-4/A filed November 10, 2026)
- Topline Phase 3 results expected in 2028
- Potential NDA submission to the FDA following positive Phase 3 results
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Werewolf Therapeutics, Inc. 425 HOWL ·Originating report